Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford is delighted to announce that the first collaborative research projects to be agreed by the University under the Pfizer Rare Disease Consortium have been signed.

The collaborations are the result of a strategic alliance to develop new treatments for rare diseases which was put in place by the University of Oxford, Imperial College London, University College London, King’s College London, Queen Mary University London, and Cambridge University acting through GMEC Pfizer will be collaborating with the University of Oxford in haematology and neuromuscular disorders. Michael Skynner, Head of Rare Disease Alliances, Pfizer, says “I am delighted to see concrete output from the first Pfizer Rare Disease Consortium call for proposals with GMEC, in the form of three funded research proposals at the University of Oxford. I look forward to a close scientific interaction between Oxford and Pfizer over the next three years”.

Congratulations to the successful Principal Investigators:

  • Professor Dame Kay Davies and Professor Matthew Wood from the Department of Physiology, Anatomy and Genetics.
  • Professor Alexander Drakesmith and Professor Simon Draper from the Weatherall Institute for Molecular Medicine and the Jenner Institute respectively.
  • Dr Wyatt Yue from the Structural Genomics Consortium.

We wish them good luck for their research!

Similar stories

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Professor Dame Frances Ashcroft to receive Vanderbilt Prize in Biomedical Science

The Vanderbilt Prize in Biomedical Science recognises women scientists with a stellar record of research accomplishments who also have made significant contributions to mentoring other women in science.

Annie Park to advance our understanding of how the brain encodes reward with new Wellcome Trust Award

Congratulations are in order for Postdoctoral Fellow Dr Annie Park who has been awarded a prestigious Wellcome Early-Career Award.

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Unlocking the Secrets of cAMP Signalling in the Heart: A Pathway to Targeted Therapeutics

A new Zaccolo group study has revealed key new insights into the role of cAMP signalling in both healthy and disease settings within the heart. They have identified new cAMP nanodomains in cardiac muscle cells that have far reaching implications for the treatment of heart disease.